Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
224.7 USD | -0.95% | -1.55% | +2.26% |
Jun. 07 | Steris Insider Sold Shares Worth $839,960, According to a Recent SEC Filing | MT |
Jun. 07 | Steris Insider Sold Shares Worth $1,132,535, According to a Recent SEC Filing | MT |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.46 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.5 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.26% | 22.44B | B- | ||
-2.20% | 187B | C+ | ||
+0.93% | 110B | C | ||
-1.77% | 69.54B | A | ||
+14.29% | 46.37B | B- | ||
-6.15% | 46.05B | B- | ||
+7.97% | 42.54B | B+ | ||
+18.53% | 30.72B | B | ||
+17.70% | 25.62B | A- | ||
-7.23% | 23.32B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STE Stock
- Ratings STERIS plc